12:55 AM EST, 11/04/2026 (MT Newswires) -- Middle East Pharmaceutical Industries Co. (SASE:4016), d/b/a Avalon Pharma, logged 15.4 million Saudi riyals in net profit attributable to shareholders for the third quarter, compared with 8.3 million riyals a year ago. EPS moved to 0.44 riyal from 0.24 riyal year over year, a Wednesday filing showed. For the three months ended Sept. 30, revenue was 124.4 million riyals versus 108.0 million riyals previously, the Tadawul-listed pharmaceutical company added.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.